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Abstract 
There has been much recent debate concerning the relative clinical utility of symptom 
dimensions versus conventional diagnostic categories in patients with psychosis. We 
investigated whether symptom dimensions rated at presentation for first-episode psychosis 
(FEP) better predicted time to first remission than categorical diagnosis over a four-year 
follow-up. The sample comprised 193 FEP patients aged 18-65 years who presented to 
psychiatric services in South London, UK, between 2006 and 2010. Psychopathology was 
assessed at baseline with the Positive and Negative Syndrome Scale and five symptom 
dimensions were derived using Wallwork/Fortgang’s model; baseline diagnoses were 
grouped using DSM-IV codes. Time to start of first remission was ascertained from clinical 
records. The Bayesian Information Criterion (BIC) was used to find the best fitting 
accelerated failure time model of dimensions, diagnoses and time to first remission. Sixty 
percent of patients remitted over the four years following first presentation to psychiatric 
services, and the average time to start of first remission was 18.3 weeks (SD=26.0, 
median=8). The positive (BIC=166.26), excited (BIC=167.30) and disorganised/concrete 
(BIC=168.77) symptom dimensions, and a diagnosis of schizophrenia (BIC=166.91) 
predicted time to first remission. However, a combination of the DSM-IV diagnosis of 
schizophrenia with all five symptom dimensions led to the best fitting model (BIC=164.35). 
Combining categorical diagnosis with symptom dimension scores in FEP patients improved 
the accuracy of predicting time to first remission. Thus our data suggest that the decision to 
consign symptom dimensions to an annexe in DSM-5 should be reconsidered at the earliest 
opportunity. 
 
Key words: accelerated failure time model; diagnosis; psychosis; remission; schizophrenia; 
symptom dimensions 
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1. Introduction  
The wide variability in treatment response among patients with first-episode 
psychosis (FEP) can be understood by viewing psychosis as involving heterogeneous 
disorders with diverse clinical presentations (Keshavan et al., 2013). Currently, the validity of 
traditional diagnoses is highly debated (Jablensky, 2016), and their link to the treatment and 
prognosis of psychotic disorders remains uncertain (Bentall, 2006; van Os et al., 1999). 
Instead, some postulate that psychosis symptom dimensions may be more useful in 
providing information about need for care and prognosis (Allardyce et al, 2007; Bakker et al., 
2013; Demjaha et al., 2009). Although the ideal number and features of these dimensions is 
not confirmed, many studies suggest a symptom dimension model comprising five specific 
constructs (i.e., positive, negative, disorganised, mania, and depression symptoms) (van Os 
& Reininghaus, 2016). Based on previous work, Wallwork et al. (2012) derived a consensus 
five-factor model of psychosis that comprised positive (e.g., delusions, hallucinatory 
behaviour), negative (e.g., blunted affect, emotional withdrawal), disorganised/concrete (e.g., 
conceptual disorganisation, difficulty in abstract thinking), excited (e.g., excitement, hostility), 
and depressed (e.g., depression, guilt feeling) dimensions. This Wallwork/Fortgang model of 
psychosis (Wallwork et al., 2012) has been shown to be the most robust factorial solution for 
exploring symptom profiles in patients with psychosis (Langeveld et al., 2013); thus we will 
use this model in the present study. 
Remission is one of the most commonly used indicators of treatment efficacy and 
response in psychosis (Lasser et al., 2007). Although 40-70% of patients with FEP achieve 
remission at some point over the course of their illness (Austin et al., 2013; Emsley et al., 
2006; Lambert et al., 2006; Langeveld et al., 2012), predicting those who will remit, and how 
long this will take, remains challenging. Previously, age of illness onset and duration of 
untreated psychosis have been linked to time to remission (Malla et al., 2006), but the 
influence of symptom dimensions expressed at presentation to services has not yet been 
investigated in comparison to traditional diagnostic categories. 
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The DSM-5 schizophrenia panel initially recommended that symptom dimensions 
should be used to supplement categorical diagnosis but ultimately this view was rejected 
(van Os, 2015). In the present study, we compared the utility of psychosis symptom 
dimensions derived using the Wallwork/Fortgang five-factor model (Wallwork et al., 2012) 
with conventional diagnostic categories to predict time to first remission in a well-
characterised sample of patients presenting to psychiatric services for the first time with 
psychosis. We hypothesised that the symptom dimensions would provide a more accurate 
prediction of time to first remission than diagnostic categories. Building on previous research 
which highlighted that combining dimensional measures with categorical diagnoses is more 
informative than considering them separately (Allardyce et al., 2007), we further tested 
whether combining symptom dimensions with categorical diagnoses led to a more robust 
model for predicting time to first remission. As the evidence suggests that the first 3-5 years 
after first illness onset constitutes a critical period for intervention (Crumlish et al., 2009), we 
focused on the first four years of illness after first contact with mental health services for 
psychosis. 
 
2. Methods 
2.1. Sample 
Participants were recruited as part of the National Institute for Health Research (NIHR) 
Biomedical Research Centre (BRC) Genetics and Psychosis (GAP) study conducted in 
South London, UK. Further details of the sample are available in Di Forti et al. (2014). 
Briefly, this study included patients aged 18-65 years who presented to psychiatric services 
of the South London and Maudsley (SLaM) National Health Service (NHS) Mental Health 
Foundation Trust between December 2006 and October 2010 with a first episode of 
psychosis (Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV; American 
Psychiatric Association, 1994). In total, 236 FEP patients were rated on the Positive and 
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Negative Syndrome Scale (PANSS; Kay et al., 1987); 82% (N=193) of these were 
successfully traced four years after first contact with mental health services. Therefore, this 
study involves retrospective analysis of the data collected prospectively for these 193 cases. 
Ethical permission was obtained from the SLaM and the Institute of Psychiatry Research 
Ethics Committee. All patients gave informed written consent after reading a detailed 
information sheet. 
 
2.2. Measures at baseline 
2.2.1. Socio-demographic characteristics. Information on socio-demographic characteristics 
was collated using a modified version of the Medical Research Council (MRC) Socio-
demographic Schedule (Mallett et al., 2002). Ethnicity was self-ascribed using the 16 
categories employed by the UK Census in 2001 (http://www.ons.gov.uk/ons/guide-
method/census/2001/index.html).  
 
2.2.2. Clinical assessments at baseline. Age at first contact was defined as age at which a 
patient was first in contact with mental health services due to their psychotic symptoms 
(McKenzie et al., 2001). Duration of untreated psychosis (DUP) was defined as the time 
between the date of appearance of the first psychotic symptom and the date of treatment 
with antipsychotic medications (Norman & Malla, 2001). The 30-item PANSS (Kay et al., 
1987) was conducted in face-to-face interviews with patients to assess psychotic symptoms 
over the preceding week. In the present study, researchers underwent comprehensive 
training in administering the PANSS and had to demonstrate a high degree of comparability 
in their practice ratings with expert raters. Although not formally tested here, high levels of 
inter-rater reliability have previously been demonstrated after sufficient training (Kay et al., 
1988; Muller & Wetzel, 1998). Baseline diagnoses were derived from interviews and mental 
health records using the Operational Criteria Checklist for Psychotic Illness (OPCRIT) 
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(McGuffin et al., 1991). The diagnoses were grouped using DSM-IV codes into 
schizophrenia (295), schizophreniform disorder (295.40), affective psychoses (296, 296.24, 
296.44), schizoaffective disorder (295.70), and other psychoses (297.1, 198.9).  
 
2.3. Tracing patients at follow-up  
Approximately 4 years (M=4.4, SD=1.8; 839 person years) after first contact with psychiatric 
services for psychosis, we sought to trace all 236 FEP cases included in the original GAP 
study and who had given consent for their clinical records to be accessed at follow-up. The 
tracing procedure is outlined in Figure 1 and further information provided in Supplementary 
Materials. During the first four years of follow-up, of all FEP cases, 15 (6.4%) had emigrated, 
5 (2.1%) had died, and 7 (3.0%) were excluded as these patients did not have information 
on follow-up and their contact details were not available at baseline to enable us to trace 
them either via their GP or ONS/GRO tracing procedures. Those who had died tended to be 
significantly older at study entry (Supplementary Table 1). We were unable to trace 16 
(6.8%) patients via electronic records. Ultimately, we successfully traced 93.2% of our 
original sample and information on first remission, time to first remission and other variables 
collected at follow-up was available for 81.8% (N=193/236) of patients.  
 
2.3.1. Measures at 4-year follow-up  
Information on outcomes was collated from clinical records using the World Health 
Organisation (WHO) Life Chart Schedule (LCS) extended version (WHO, 1992). We used 
this measure at the end of the follow-up period to obtain standardised retrospective 
assessments of patients’ experiences, clinical and social outcomes for the entire period of 
illness operationalised as the period from the first contact with mental health services for 
FEP to the date of the last assessment recorded in electronic notes. The LCS measure has 
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been widely used in prospective and retrospective studies (Ajnakina et al., 2017; Morgan et 
al., 2014; Schoeler et al., 2017; van Os et al., 1996), and has been shown to be reliable for 
follow-up assessments and adaptable across cultures (Jablensky et al., 1992, Susser et al., 
2000). 
 
2.3.1.1. Clinical assessment at follow-up. Similar to previous research (Morgan et al., 2014) 
using information extracted from clinical records, first remission was operationalised as the 
very first continuous period of ≥6 months of a complete absence of a clear record of 
psychotic symptoms in clinical notes, including no evidence of re-emergence of psychotic 
symptoms, re-admission to psychiatric wards, and/or having been re-referred to acute home 
treatment/crisis intervention services during the follow-up period (Ajnakina et al., 2017). This 
definition did not depend on whether non-psychotic symptoms (e.g. depressed mood, 
neurotic manifestations) were absent, or whether patients were receiving treatment with 
antipsychotic medications during this period of remission. This definition of remission has 
been shown to be as reliable and robust as other definitions of remission in FEP patients 
available in the literature (Lally et al., in press), including the consensus definition outlined by 
Andreasen et al. (2005). Time to first remission was defined as the period from the date of 
first contact with mental health services for FEP to the date of first complete absence of a 
clear record of psychotic symptoms in clinical notes as indicated above for ≥6 months 
(Loebel et al., 1992). Those patients who had not remitted at all during the 4-year follow-up 
period were assigned a value of 208 weeks (i.e., full 4 years) as is customary in survival 
analysis. Similar to previous reports (Schoeler et al., 2017), adherence to antipsychotic 
medications over the course of follow-up was assessed on a three-point scale indicating the 
proportion of time a patient was estimated to be taking antipsychotic medications as 
prescribed (1: 0-33% of the 4-year period; 2: 34-66%; and 3: 67-100%). Those patients 
whose psychiatrists advised them to stop taking antipsychotics were defined as fully 
adherent with this treatment.  
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2.3.1.2. Social outcomes and drug use. Using the LCS, we collected from the electronic 
clinical case records information on socio-demographics, such as living arrangements, 
relationship status, and substance use during the follow-up period.  
 
2.4. Analysis 
All tests for analyses described in this section were two-tailed and a p<0.05 was considered 
statistically significant. All analyses were conducted in STATA release 14 (STATA Corp LP, 
USA). 
 
2.4.1. Confirmatory factor analysis (CFA). CFA was conducted to evaluate the statistical fit 
(Stefanovics et al., 2014) of the Wallwork/Fortgang’s five-factor model of psychosis 
(Wallwork et al., 2012) in patients with FEP. This model includes positive (P1, P3, P5, G9), 
negative (N1, N2, N3, N4, N6 and G7), excited (P4, P7, G8 and G14), disorganised/concrete 
(P2, N5, G11), and depressed (G2, G3, G6) factors. The detailed description of methods 
employed to conduct CFA using this sample is available in Ajnakina et al (2016) and further 
information is provided in the Supplementary Materials.  
 
2.4.2. Association analyses and model selection. Because the assumption of proportional 
hazards for the traditional Cox regression analysis was not regularly met, we chose an 
accelerated failure time model (AFT) for right censored data. The AFT model assumes that 
the effect of a covariate is to either accelerate or decelerate the life course of illness by some 
constant rather than assuming the effect is constant over time (Sastry, 1997). The parameter 
coefficients in the AFT model were converted into percentage differences in time to first 
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remission through the equation: ((eβ -1) x 100%) (Holtz et al., 2006). This means that the 
median difference in time to first remission is ((eβ -1) x median time to first remission (i.e., 8 
weeks)). A more detailed description of the AFT models chosen for the study, their 
parameters and interpretations of results are provided in Supplementary Table 2 and the 
Supplementary Materials.  
Next using Bayesian Information Criterion (BIC) and ΔBIC scores for each of these 
models, we compared the performance of all AFT models that included the symptom 
dimensions and diagnostic categories individually and in combination as predictors of time to 
first remission. The ΔBIC was defined as the BIC score for the model minus the score for the 
model with the lowest BIC score (Elderd et al. 2013). Therefore, the best model will have a 
ΔBIC score of 0. Models >4 units away from the best model (ΔBIC>4) are considered to be 
significantly inferior (Elderd et al., 2013).  
To identify potential confounding variables, we examined variables collected at 
baseline (i.e., age at first contact with mental health services, relationship and employment 
status, living arrangements, educational attainments, DUP, and illicit substance use) and 
during follow-up (i.e., medication adherence, relationship and employment status, living 
arrangements and illicit substance use) by conducting univariate analysis with time to first 
remission as the dependent variable. The covariates with p<0.20 were considered for our 
multivariate model. We eliminated the variables with the largest p-values individually until all 
the remaining variables had p<0.05. This procedure highlighted age at first contact, DUP, 
and illicit substance use during the follow-up period as significant confounding factors. As 
evidence suggests that medication adherence over the course of follow-up is an important 
confounding factor for time to remission (Malla et al., 2006), we additionally included this 
variable in our final analyses.  
 
3. Results 
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3.1. Patient characteristics  
The demographic characteristics of the 193 patients and remission of psychosis over four-
year follow-up are presented in Table 1. The mean age at first contact was 28.2 years 
(SD=98.2); 64.8% of the sample were men; almost two-thirds of the sample had a diagnosis 
of schizophrenia or schizophreniform disorders; and 34.2% were of White ethnicity, though 
the largest ethnic group in this sample was of Black ethnicity (39.9%).  
 
3.2. Confirmatory factor analysis  
The CFA produced an excellent fit of the model: CFI=0.959, RMSEA=0.052 (90% CI=0.037-
0.067) and SRMR=0.071. Patients with a baseline diagnosis of schizophrenia had higher 
scores on the disorganised/concrete symptom dimension compared with all other diagnostic 
categories (F=3.60, df=185, p=0.001). There were no other significant differences between 
baseline diagnostic categories on the five symptom dimensions (Figure 2).  
 
3.3. Time to first remission 
The rate of remission during the first four years of illness was 59.1% and the average time to 
the start of the first period of remission was 18.3 weeks (SD=26.0; median=8, IQR=5-20). 
Those who did not remit (N=76) showed more severe scores on the disorganised/concrete 
symptom dimension compared to remitters at the time of study entry though this just fell 
short of statistical significance (t=1.89, df=183, p=0.06). There were no other significant 
differences in symptom dimensions at baseline between remitters and non-remitters.  
 
3.4. Associations between time to first remission and symptom dimensions vs diagnostic 
categories 
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Multivariate AFT model estimates of time to first remission over the first four years of follow-
up are provided in Table 2. The results showed that a 1-unit increase in the positive 
symptom dimension measured at baseline was associated with an increase of 8.3% in the 
time to first remission. Consequently, an increase of 1 unit in the positive symptom 
dimension corresponds to a median increase of the time to first remission of 4 days. 
Similarly, 1-unit increase in the excited dimension was associated with an increase of 18.5%, 
and in the disorganised/concrete dimension was associated with an increase of 4.8% to first 
remission. An increase of 1-unit in the combined five symptom dimensions corresponds to a 
median increase of the time to first remission of 7 days. Furthermore, the baseline diagnosis 
of schizophrenia was significantly associated with an increase of 27.0% of time to first 
remission compared to non-schizophrenia diagnoses; this entails a median increase of the 
time to first remission of 2 weeks. Finally, 1-unit increase in the score that combined both the 
baseline diagnosis of schizophrenia with all five symptom dimensions was associated with 
an increase of 8.3% of time to first remission, which equates to a median increase of the 
time to first remission of 4 days. 
 
3.5. Choosing the best model for predicting time to first remission  
The results of the BIC and ΔBIC analyses are presented in Table 3. Compared to all five 
categorical diagnoses singularly (Models 7-11), using symptom dimensions individually as 
predictors of time to first remission did not result in models with a better performance 
(Models 1-5). Using all five categorical diagnoses in combination produced a model (Model 
12) with an equal performance to the model that combined all five symptom dimensions 
(Model 6) in predicting time to first remission. Further analyses showed that supplementing 
baseline diagnosis of schizophrenia with the five symptom dimensions generated the best 
fitting model (Model 13) for predicting time to first remission. Compared to this best fitting 
model (Model 13), Models 1, 2, 6, and 7 demonstrated a reasonable (ΔBIC<4) but inferior 
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(ΔBIC>0) fit to the data. Although Model 9 shows that affective psychosis diagnosis is 
significantly associated with decreased time to first remission, the results of the BIC and 
ΔBIC analyses highlight this model has significantly poorer performance compared to the 
best fitting model (Model 13). Therefore, this model does not perform well enough to warrant 
validity.  
 
4. Discussion  
This is the first longitudinal study to have examined the predictive value of dimensional and 
diagnostic approaches, both individually and in combination, in predicting and quantifying 
time to first remission in FEP patients during the initial four years after first contact with 
psychiatric services. This extends previous work focusing on symptom dimensions and rates 
of remission in FEP (Emsley et al., 2006, 2007). We found that the positive, excited and 
disorganised/concrete dimensions of psychosis were important predictors of time to first 
remission in our sample. In demonstrating this in FEP patients, we have produced an 
important first step in mapping these putative markers of response onto illness outcome. Not 
surprisingly, we found that of all diagnostic categories examined in this study schizophrenia 
was the only one associated with a longer time to first remission. This observation is 
consistent with a characterisation of this disorder as one with lower rates of remission and a 
more disabling course than other psychotic disorders (Harrow et al., 2000; Jaaskelainen et 
al., 2013). However, in contrast to our hypothesis, psychosis symptom dimensions were not 
superior to the traditional diagnostic categories in predicting time to first remission. In fact, 
the combination of the baseline diagnosis of schizophrenia with the five symptom 
dimensions produced the best model fit. This may be because combining a categorical 
diagnosis of schizophrenia with higher scores on symptom dimensions indexes greater 
severity of psychotic illness at first presentation to services. 
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These results also have important implications for the current diagnostic classification 
systems. There is a growing consensus that the combination of the categorical approach 
with symptom dimensions allows a more accurate classification of affected individuals into 
categorical diagnoses based on profiles of specific symptom dimensions (Reininghaus et al., 
2013; van Os & Kapur, 2009). The continuous dimension scores further enhance the 
classification by adding information on the severity of psychopathology (van Os & 
Reininghaus, 2016). Our findings extend this further by showing that considering the 
categorical and dimensional approaches together provides greater information about 
patients’ need for care and treatment response after first contact with mental health services. 
Therefore, our results suggest that it was most unfortunate that symptom dimensions were 
relegated to an Annexe within DSM-5. This should be reconsidered at the earliest 
opportunity. 
 
4.1. Strengths   
The five-factor model of psychosis symptoms employed in the present study was selected 
for being a consensus model derived from existing studies (Wallwork et al., 2012) that has 
been shown to be optimal for use in FEP samples (Langeveld et al., 2013). We have 
undertaken a thorough approach to data extraction from clinical records and tracing patients, 
thus ensuring a low level of attrition. Additionally, we employed a definition of remission with 
demonstrated robust validity and reliability (Lally et al., in press). The symptom dimensions 
were founded on the PANSS which has previously been shown to be resilient to the effects 
of age, severity of symptoms, chronicity of illness (White et al., 1997) and short-term 
medication withdrawal (Lindenmayer et al., 1994). Moreover, the sample utilised in the 
present study was a well-characterised sample of recent-onset patients presenting for the 
first time with psychosis and thus the findings are not likely to be confounded by chronicity of 
illness or prolonged medication use.  
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4.2. Limitations  
Nearly 80% of our patients were recruited from inpatient units; this may imply that very early 
remitters might not have been fully represented from the start. Follow-up studies tend to 
suffer from systematic bias due to the non-random loss of information during the follow-up 
period. Nonetheless, we reduced the risk for this potential bias by establishing the 
whereabouts, deaths and emigration status for 93% of our sample. It is possible that 
clinicians might not always have recorded in the electronic notes when symptoms were 
present and thus in some cases patients may have been classified inaccurately as remitters. 
Similarly, in some cases inaccuracies in classification may have occurred as electronic notes 
might not always have contained information on patients’ well-being for periods when they 
were not in contact with mental health services. Nonetheless, it has been shown that it is 
possible to reliably quantify the course of disorder using routine data from clinical notes 
(Bebbington et al., 2006). Moreover, our thorough approach to data extraction from clinical 
notes has ensured that the rates of remission and time to first remission reported in this 
study are consistent with earlier studies which collected data from face-to-face interviews 
only (Revier et al., 2015), extracted it retrospectively from clinical notes (Ajnakina et al., 
2017; Bromet et al., 2005; Harrison et al., 2001; Kohler et al., 2009) or employed both 
approaches (Morgan et al., 2014; Schoeler et al., 2017). Many diagnostic categories 
assigned to patients on first contact with mental health services may either be provisional or 
likely to change over the illness course (Schwartz et al., 2000), as seen in our sample with a 
relatively high number of patients with a diagnosis of schizophreniform disorder. 
Nevertheless, in the present study we focused on the baseline diagnosis, rather than the 
diagnosis obtained at the end of the follow-up period, to emulate the naturalistic setting for 
all patients with FEP when predicting time to first remission depending on the diagnosis 
received at the very first contact with psychiatric services. Finally, it is imperative to 
investigate the predictive power of our best fitting model in a large independent sample. 
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Additionally, in this study we specifically focused on symptom dimensions and diagnostic 
categories but it would be useful for future studies to expand our best fitting model to 
incorporate a wider range of potential predictors of time to first remission (e.g., see Emsley 
et al., 2006, 2007). 
 
4.3. Conclusion 
Our findings indicate that the use of a combination of five symptom dimensions and the 
traditional diagnostic classification of psychosis provides a more robust prediction of the 
length of time that it would take for patients to respond to treatment after the first contact with 
mental health services for FEP. The results of this study should be replicated in other 
prospective cohorts with larger samples.  
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Figure Legends 
Figure 1. Flow chart documenting how psychosis patients were traced and administrative 
outcomes four years after first contact with mental health services for a first episode of 
psychosis (FEP). 
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Figure 2. Five psychosis symptom dimension mean scores by traditional diagnostic 
categories. Graphs display the mean psychosis symptom dimension scores for first-episode 
psychosis patients with a DSM-IV diagnosis of schizophrenia, affective psychosis, 
schizophreniform disorder, schizoaffective psychosis, and other psychoses at first 
presentation to psychiatric services (double-headed lines indicate standard deviations). The 
continuous symptom dimension scores were derived using the ‘predict’ post-estimation 
command in Stata following a confirmatory factor analysis of the Wallwork/Fortgang five-
factor model (Wallwork et al., 2012) of the items from the Positive and Negative Syndrome 
Scale. The five dimensions capture positive, negative, disorganised/concrete, excited, and 
depressed symptom items at first presentation to psychiatric services for psychosis  
***p<0.001 
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Table 1. Sample characteristics at baseline and remission of psychosis over four-year 
follow-up from first presentation to mental health services 
Baseline sample characteristics and 
remission at follow-up 
Total sample 
N=193 
 Mean (SD) / n (%) 
  
Age years  28.2 (8.2) 
 Range 18-60 
   
Gender  
 Female 68 (35.2) 
 Male  125 (64.8) 
   
Ethnicity   
 White (all groups) 66 (34.2) 
 Black (all groups) 77 (39.9) 
 Other 50 (25.9) 
   
Diagnosis  
 Schizophrenia  55 (28.5) 
 Schizophreniform 52 (28.5) 
 Affective psychoses 44 (22.8) 
 Schizoaffective psychosis 26 (13.5) 
 Other psychoses 16 (8.3) 
   
On antipsychotic medication at study entry  184 (96.3) 
   
DUP days  35.0 (118.6) 
   
Years of follow-up 4.4 (1.8) 
 Median (IQR) 4 (3-5) 
   
Rate of remission 110 (59.1) 
   
Time to first remission weeks 18.3 (26.0) 
 Median (IQR)  8 (5-20) 
 
DUP, duration of untreated psychosis. IQR, Interquartile range. SD, standard deviation. 
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Table 3. Comparisons of the fit of all significant models using BIC scores and ΔBIC 
 
Models Predictors of time to first remission BIC ∆BIC 
Symptom dimensions   
 Model 1 Positive dimension 166.26 1.91 
 Model 2 Excited dimension 167.30 2.95 
 Model 3 Negative 173.39 9.04 
 Model 4 Disorganised/Concrete 168.77 4.42 
 Model 5 Depressed 173.14 8.79 
 Model 6 All 5 psychosis dimensions 166.36 2.01 
     
Diagnostic categories   
 Model 7 Schizophrenia 166.91 2.56 
 Model 8 Schizophreniform disorder 173.08 8.73 
 Model 9 Affective Psychoses 169.03 4.68 
 Model 10 Schizoaffective psychoses 173.27 8.92 
 Model 11 Other psychoses 172.83 8.48 
 Model 12 All five diagnostic categories 171.13 6.78 
     
Combination of both approaches   
 Model 13 Schizophrenia diagnosis and all 5 
psychosis dimensions 
164.35 0 
 
BIC, Bayesian Information Criterion; ΔBIC is defined as the relevant model minus the model with the lowest BIC 
score. All models are adjusted for age at the time of first contact with mental health services for psychosis, 
duration of untreated psychosis, substance use measured during the four-year follow-up period, and 
antipsychotic medication adherence over the course of follow-up. The model in bold provides the best fit (i.e., the 
lowest BIC score). 
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